As pharmaceutical companies race to reduce the time and cost of bringing new therapies to market, a new generation of biotech platforms is emerging to rethink how research is conducted. Helical is at the forefront of this shift, securing $10 million in seed funding to develop a virtual AI powered lab designed to transform drug discovery workflows.
Strong Backing from AI and Biotech Investors
The funding round was led by redalpine, with participation from Gradient, BoxGroup, and Frst. The round also attracted prominent angel investors, including Aidan Gomez, Clement Delangue, and Mario Götze.
This combination of investors reflects growing interest in platforms that combine artificial intelligence with real world scientific applications.
Addressing a Core Bottleneck in Pharma R&D
Founded in 2024 by Rick Schneider, Maxime Allard, and Mathieu Klop, Helical focuses on one of the most persistent challenges in drug discovery, the limited throughput of physical experimentation.
While advances in biological foundation models allow researchers to test hypotheses computationally, many organisations struggle to convert these insights into actionable and reproducible scientific outcomes. This gap often slows down decision making and extends development timelines.
Helical aims to bridge this divide by integrating computational predictions with biological validation in a unified system.
A Virtual AI Lab for Collaborative Science
At the heart of Helical’s offering is a virtual AI lab that transforms theoretical models into practical discovery workflows. The platform is built around two interconnected components.
The Virtual Lab is designed for biologists and translational scientists, enabling them to run experiments, analyse results, and validate hypotheses. The Model Factory, on the other hand, is tailored for machine learning engineers and data scientists, allowing them to develop and refine models.
By operating on shared datasets and results, the platform fosters collaboration between teams that have traditionally worked in silos. This integrated approach supports more consistent and evidence based decision making throughout the research process.
Accelerating Discovery Timelines
Helical’s technology is already being used by several top 20 global pharmaceutical companies. Across applications such as target identification, biomarker discovery, and therapeutic design, the platform has demonstrated the ability to significantly reduce discovery timelines.
By enabling teams to move from hypothesis to decision in days rather than months, the platform addresses one of the key inefficiencies in pharmaceutical research.
This capability is particularly valuable in an industry where rising costs and lengthy development cycles have become major challenges.
Expanding Across Therapeutic Areas
With the new funding, Helical plans to deepen its deployments with existing clients and expand into additional therapeutic areas. The company will also continue to develop its platform, with a focus on enhancing its evidence layer to improve performance across different diseases.
This includes refining how data is integrated and analysed, ensuring that insights generated by the platform are both reliable and actionable.
Shaping the Future of Drug Discovery
Helical’s approach reflects a broader transformation in biotechnology, where artificial intelligence is moving from a supporting role to a central component of research and development.
By combining computational power with real world validation, the company is helping to create a new model for scientific discovery, one that is faster, more collaborative, and more efficient.
As the pharmaceutical industry continues to evolve, platforms like Helical’s virtual AI lab could play a critical role in accelerating innovation and bringing new treatments to patients more quickly. With strong backing and early traction, Helical is positioning itself as a key player in this emerging landscape.